You are here: Welcome to the MPKB » Welcome to the MPKB » Health, food and drink » Aiming at Health » Health Maintenance and Olmesartan
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:food:aim_health:aging [01.10.2019] – [With additional studies] sallieqhome:food:aim_health:aging [01.11.2019] – [with additional studies] sallieq
Line 14: Line 14:
  Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}}))   Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}})) 
  
 + The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) 
 +
 +The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}})) 
 +
 +Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}})) 
 +
 +==== general research on aging ====
 +
 +Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. (({{pubmed>long:25539567}})) 
  
 ==== Some of the documented protective effects of ARBs ==== ==== Some of the documented protective effects of ARBs ====
home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.